3 not yet recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 3 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow EGFR Mutation: new trials by email Literature Review of EGFR Mutation trials Research Report on EGFR Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study Furmonertinib, carboplatin, pemetrexed - Non-small Cell Lung Cancer (NSCLC), Brain Metastases | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-01-01 | 2026-01-26 |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Combination therapy prospective cohort - Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Not yet recruiting | Qiming Wang | 100 | 2025-05-15 | 2025-05-14 |
Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Central Nervous System Neoplasms (2) · Lung Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Meningeal Neoplasms (1)
Carboplatin (1) · Pemetrexed (1) · aflutinib (1) · osimertinib (1)
Beijing Pearl Biotechnology Limited Liability Company (1) · Qiming Wang (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (1) · United States (1)